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Abstract
Background Ultrasound guided cardiac shock wave
therapy (CSWT) is a noninvasive therapeutic option in the
treatment of chronic-refractory angina. Clinical trials have
shown that CSWT reduces angina symptoms, improves
regional systolic function, LV ejection fraction, myocardial
perfusion and quality of life parameters. Absolute mea-
surements of myocardial perfusion before and after CSWT
have not been performed so far.
Methods and results We studied a total of 21 CCS III
patients with history of CAD and multiple interventions
who suffered from disabling angina despite individually
optimized medical therapy. An N-13 NH3 PET perfusion
scan under adenosine was performed before and after
CSWT treatment. CSWT was well tolerated in all patients.
Absolute perfusion under adenosine of the global left-
ventricular myocardium did not change under therapy or
minimal coronary resistance. The treated segments, how-
ever, showed in terms of both perfusion and resistance a
mild but significant improvement, by 11 and 15 %, re-
spectively, whereas no change could be observed in the
remote segments. Considering a threshold of increased
perfusion of 5 %, 10 (77 %) out of 13 patients with a better
target perfusion improved in their CCS class, whereas 3
(43 %) out of 7 patients without improved target perfusion
improved in their CCS class too.
Conclusion Standard CSWT has the potential to improve
myocardial perfusion of the therapy zone and clinical CAD
symptomatology without affecting global myocardial per-
fusion. As a noninvasive and well tolerated therapeutic
option, these data suggest the use of CSWT in patients with
end-stage CAD.
Keywords Coronary artery disease  Cardiac shock wave
therapy  Refractory angina  Myocardial perfusion
imaging  PET
Introduction
Coronary artery disease (CAD) is one of the leading causes
of morbidity and mortality in industrialized countries. Sev-
eral therapeutic options for chronic CAD are available. They
include medical treatment, percutaneous coronary inter-
vention (PCI), and coronary artery bypass surgery. Despite
excellent interventional results, an increasing number of
patients with advanced CAD not suitable for any interven-
tion suffer from chronic angina inspite of optimal medical
therapy [1, 2]. It has been shown that persistent angina
symptoms are associated with long-term anxiety, depres-
sions, impaired physical functioning and QOL [3]. There-
fore, several alternative therapeutic approaches, including
epidural spinal cord stimulation (SCS) [4], enhanced exter-
nal counterpulsation (EECP) [5], transmyocardial laser
revascularization (TMR) [6], or induction of angiogenesis by
protein, gene stem cell-based therapies [7] have been pro-
posed. These alternatives are invasive, still at a preclinical
stage, or already outdated.
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Ultrasound guided cardiac shock wave therapy (CSWT)
is another noninvasive therapeutic option in the treatment
of chronic-refractory angina. Physically, a shock wave
pulse is a single sharp pressure pulse with amplitude up to
100 MPa, followed by a tensile part of several microsec-
onds with lower amplitude.
Animal studies have suggested that CSWT promoted
angiogenesis in ischemic myocardium by mRNA expres-
sion of vascular endothelial growth factor (VEGF), en-
dothelial cell proliferation, and endothelial nitric oxide
synthase (eNOS) expression [8, 9]. Furthermore, nonen-
zymatic nitric oxide production by CSWT could be
demonstrated [10].
Clinical trials demonstrated that CSWT may reduce
angina symptoms, improve regional systolic function, LV
ejection fraction, myocardial blood flow and quality of life
parameters [11–14].
In this context myocardial perfusion has been evaluated
with SPECT imaging at rest [15], under low-dose dobu-
tamin stimulation [11, 13], on exercise [16] and under
dipyridamole-induced hyperemia [17], all without absolute
quantification. The present study evaluated with N-13 NH3
PET perfusion imaging under adenosine induced hyper-
emia the effects of CSWT treatment on absolute perfusion
in the target region and in the entire left myocardium in
patients with chronic-refractory angina.
Methods
Patient population and study protocol
We studied a total of 21 patients with history of CAD and
multiple prior interventions (PCI, CABG, or both) who
suffered from disabling angina despite individually opti-
mized medical therapy (Table 1).
An N-13 NH3 PET scan at rest and under adenosine was
performed for clinical reasons to reevaluate a repeat
mechanical revascularization. If reintervention had been
found inappropriate, the viable myocardial wall with the
leading perfusion abnormality was identified for CSWT.
The baseline PET scan was performed 21 ± 36 days be-
fore onset of therapy. A repeat PET scan was performed
43 ± 27 days after the last CSWT session for clinical
reasons, to verify the therapeutic effect on regional perfu-
sion and to decide upon continuation of therapy.
Canadian Cardiovascular Society (CCS) scale was
assessed in all patients before and after therapy. Addi-
tionally, echocardiography and, if feasible, ergometry were
performed.
Patients gave their written informed consent to CSWT
and the clinical PET studies. The data analysis was ap-
proved by the local ethics committee of the Ruhr-Univer-
sity Bochum (Reg. No. 60/2013).
Image acquisition and stress testing
Patients were investigated with an ECAT-951 R scanner
(CTI/Siemens Medical systems) and, after a change of the
device, with a Biograph mCT (Siemens, Erlangen, Ger-
many). Directly before the PET acquisition, a transmission
scan was performed with an ECAT-951 R scanner and a
low-dose CT with the Biograph mCT for attenuation
correction.
Adenosine was infused intravenously at a constant rate
of 0.14 mg/kg/min over 6 min. During the stress phase,
heart rate and blood pressure were recorded every 2 min,
starting with the onset of the adenosine infusion until
completion of after 6 min. Mean arterial blood pressure
was calculated from the average values of all four time
points and minimal coronary resistance as mean arterial
blood pressure/global perfusion.
Two minutes after the onset of the adenosine infusion,
on average 600 MBq N-13 NH3 were injected as an in-
travenous bolus. Image acquisition over 15 min was started
simultaneously with the bolus injection. A consecutive set
of 20 frames was reconstructed for quantification of
perfusion.
Quantitative perfusion analysis
Quantification of the N-13 NH3 scans was based on an
irreversible two-compartment model [18]. Corrections for
fractional blood volume, partial volume effects and spil-
lover activity from left-ventricular blood pool to tissue
were calculated as described elsewhere [19]. A validation
of the model in humans had been performed by the argon
inert gas technique beforehand [20]. The quantification
procedure delivered 20-segment parametric polar maps of
MBF. Segments with a fractional blood volume[0.5 were
excluded from further analysis. Such large values are only
Table 1 Patient characteristics
Age 65 ± 10 years





No. of patients CAD status
CAD 21 1 with 1-, 20 with 3-vessel disease
Prior
infarction
11 7 with 1, 4 with 2 MI
Prior PCI 16 5 with 1, 6 with 2, 5 with C3 PCI
Prior CABG 19 15 with 1, 4 with 2 CABG
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explainable by spillover from the ventricle and mostly re-
ferred to the basal segments of the septum. Furthermore,
segments with a resting MBF\ 50 mL/min/100 g were
regarded as scarred and also excluded from the analysis.
Global perfusion was calculated as the average of all my-
ocardial segments [21].
The CSWT target zone was assigned to the anteroseptal
wall in 8 cases, to the inferolateral wall in 6, to the inferior
wall in 6, and to the apex in 1 case. The reference wall was
defined as the remote wall opposite to the CSWT target
zone. In the case of the apical CSWT target, the anterior
wall served as the reference. For quantitative analysis,
perfusion values of the segments of the parametric po-
larmaps representing either the target or the remote wall
were averaged.
Shock wave therapy device, procedure and protocol
A detailed description with illustration of the device and
the CSWT protocol has been given elsewhere [13]. In brief,
shockwaves were applied with a commercially available
shock wave generator (Cardiospec, Medispec, Gaitersburg,
USA) under echocardiographic guidance. The energy flux
density was adjustable between 0.03 and 0.2 mJ/mm2, with
a focus size of 8–9 mm and a length of 25 mm to ensure
transmural coverage. The focus could be set up to a depth
between 4 and 15 cm. During the procedure, patients lay in
supine position. ECG, blood pressure and vital signs were
monitored continuously.
The target region previously defined with the PET scan
was adjusted with the ultrasound probe. Shock wave re-
lease occurred with an R-wave ECG trigger.
The CSWT scheme was performed over 3 months
(93 ± 34 days) in blocks of 3 sessions applied every other
day during the treatment weeks, with 6 weeks intervals
(44 ± 25 and 42 ± 15 days, respectively). The target re-
gion previously defined with PET was divided into a basal,
midcavity, and apical zone. During each treatment, these
zones were targeted with the ultrasound probe, progressing
from the basal zone in week 1 (sessions 1–3) to the mid-
cavity zone in week 2 (sessions 4–6), and the apical zone in
week 3 (sessions 7–9). Patients received 300 shocks (when
starting) to 500 shocks (after verification of tolerance) per
treatment session. Thus, during the 9 shockwave sessions, a
total of 2700–4500 individual discharges were delivered.
Troponin I was controlled several hours after each
application.
Echocardiography
Resting two-dimensional echocardiographywas performed at
baseline and follow-up with a 1.7/3.3 MHz multifrequency
probe in harmonic imaging mode using commercially
available echo equipment (Vivid E9, General Electric, Hor-
ten, Norway). The classical two apical views (2- and
4-chamber views)were applied tomeasure biplane LVEF and
both the endsystolic and enddiastolic volumes.
Exercise stress testing
The bicycle test was performed in the upright position
(Ergometer 900 ERG, GE Medical Systems). Depending
on the patient’s condition, ergometry was started at 25 W
or 50 W, and was increased by 25 W each minute. The test
was stopped when typical chest pain, significant ST de-
pressions, or exhaustion of the leg muscles occurred.
Statistical analysis
For the sample size estimation, a power of 90 % and a
significance criterion of 0.05 were chosen. The minimum
expected difference between the two means and the stan-
dard deviation were estimated to 10 mL/min/100 g each.
Accordingly, about 20 patients had to be enrolled [22].
Data are given as mean value ± standard deviation. In
the first step, the paired parameters were tested for normal
distribution with the Kolmogorov–Smirnov test. As all
parameters were normally distributed, post hoc compar-
isons were performed with a paired t test.
The contingency between change in CCS class (un-
changed or better) and change in perfusion (increase\5 %
and increase C5) was examined using Fisher’s exact test.
Differences were considered statistically significant at
values\0.05 (two-sided). For the analyses, the statistical
software package IBM SPSS (version 20) was used.
Results
Clinical characteristics, medication, and clinical
parameters
The baseline clinical characteristics of the patients and
their cardiac medication are shown in Tables 1 and 2.
Neither dosages of long-acting nitrates nor the other car-
diac medicaments were changed during the observation
period.
CSWT was well tolerated in all patients. No patient
showed an increase in troponin I beyond the reference level
after the applications, and no therapy course had to be
stopped prematurely.
All patients were in CCS class III at baseline. At follow-
up, a downstaging was observed in 13 patients, such that 13
were in CCS class II and 8 remained in CCS class III
(Table 3).
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Exercise testing could be completed in 16 patients at
baseline and follow-up. In 5 patients, ergometry was not
feasible due to non-cardiac limitations. Mean achievable
workload at baseline was 93 ± 44 W, and at follow-up
101 ± 41 W (n.s.).
PET perfusion measurements and correlation
to CCS class
The perfusion data are listed in Tables 3 and 4. Absolute
myocardial perfusion of the global left-ventricular
myocardium under adenosine induced hyperemia did not
change under therapy, nor did minimal coronary resistance
(perfusion related to perfusion). The treated segments,
however, in terms of both perfusion and resistance, showed
a mild but significant improvement, 11 and 15 %, respec-
tively, whereas, no change could be observed in the remote
segments. Figure 1 illustrates the PET scans of a typical
case. This patient experienced a downstaging to CCS class
II.
Considering a threshold of improvement in perfusion of
5 %, based on an estimated error of measurement of 5 %,
10 (77 %) patients out of 13 with a better perfusion of the
target segments improved in their CCS class, whereas, 3
(43 %) patients out of 7 without better perfusion of the
target segments improved in their CCS class, too (Table 5).
This 5 % value was based on the general variability of
repeated PET N-13 ammonia measurements under adeno-
sine [23].
Echocardiographic measurements
The results are given in Table 6. No significant changes in
the global left-ventricular parameters enddiastolic diameter
(LVEDD), enddiastolic (LVEDV), endsystolic (LVESV)











Table 3 Target region, PET perfusion, and change in CCS class of the individual patients
Pat No. CSWT Target Perfusion of target segments Perfusion of remote segments Perfusion of the global myocardium Delta CCSa
Baseline Follow-up Baseline Follow-up Baseline Follow-up
1 Inferior 91 123 131 150 130 156 -1
2 Anteroseptal 143 152 97 104 139 149 0
3 Lateral 66 74 116 138 88 106 -1
4 Anteroseptal 87 71 141 107 105 75 0
5 Inferior 184 162 244 171 241 192 -1
6 Inferior 114 156 174 209 144 171 0
7 Anteroseptal 162 173 167 174 162 180 0
8 Lateral 67 146 123 154 101 152 -1
9 Lateral 192 220 152 192 170 192 -1
10 Lateral 77 81 106 96 99 94 -1
11 Apikal 230 227 326 311 284 302 0
12 Anteroseptal 116 130 90 96 96 95 -1
13 Lateral 76 93 134 150 94 120 -1
14 Anteroseptal 161 165 218 231 190 208 0
15 Anteroseptal 164 167 204 196 178 183 0
16 Inferior 76 101 79 91 94 103 -1
17 Lateral 119 135 140 117 157 161 -1
18 Anteroseptal 72 95 60 70 68 71 -1
19 Inferior 190 182 215 231 228 213 -1
20 Anteroseptal 77 92 115 99 82 81 0
21 Inferior 58 42 79 88 75 86 -1
PET perfusion values are given in mL/min/100 g
a -1: a change from CCS classes III to II was observed, 0: no change in CCS class
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and ejection fraction (LVEF) were observed between
baseline and follow-up.
Discussion
CSWT considers an alternative therapeutic approach in the
treatment of patients with end-stage CAD without any
further interventional option, but with angina symptoms
despite optimized individual medication. Although the
exact mechanism of CSWT in myocardial tissue is not
completely understood, the main effect seems to be a local
stimulation of neoangiogenesis. This may be induced by
two pathways: (1) increase of local shear stress by the
collapse of microbubbles, and (2) stimulation of local an-
giogenesis by angiogenesis-related growth factors and re-
cruitment of endothelial progenitor cells [8, 9, 24].
Several studies demonstrated that CSWT is able to im-
prove clinical symptoms, and quality of life parameters
[11, 12, 14]. Evaluations have been performed with several
nuclear imaging techniques. They showed, on a qualitative
basis of imaging analysis, an improvement in resting per-
fusion in 14 patients and exercise perfusion in 10 patients
[15, 16]. A more dedicated analysis in 9 patients demon-
strated an improvement in the treated area, while the un-
treated area tended to worsen [17]. One study failed to
show significant differences in myocardial perfusion in 9
patients at rest and under low-dose dobutamine stimulation
[11].
In the present study, we could demonstrate a significant
increase in absolute myocardial perfusion in the treated
segments, whereas no change in perfusion occurred in the
remote segments. Coronary resistance showed a concor-
dant behavior indicating that the perfusion changes were
not exclusively related to improvements in hemodynamics
and has to be assigned to further factors directly affecting
myocardial perfusion. CSWT-induced neoangiogenesis
may be one potential component, but the extent to which it
contributes required additional morphological studies.
Normal absolute myocardial perfusion under hyperemia
is usually assumed[200 mL/min/100 g [25]. Against this
background, mean global myocardial perfusion under
adenosine was severely diminished in our patient cohort,
but within the range of hyperemic perfusion in ischemic
heart disease [26]. The relative high standard deviation of
the individual data indicates that they extend over a long
range and that the CSWT patient group itself represents a
heterogeneous subset.
In terms of global myocardial perfusion and minimal
coronary resistance, no significant changes were found
during the 4 months between the observation periods.
These results are in accordance with the echocardiographic
measurements indicating that no significant change of the
disease occurred during this period. Nevertheless, a treat-
ment of the leading ischemic area seems to be beneficial
Table 4 PET perfusion measurements of the entire cohort
Perfusion under adenosine (mL/min/100 g) Minimal coronary resistance [mmHg/(mL/min/100 g)]
Baseline Follow-up P Baseline Follow-up P
CSWT target segments 120 ± 52 133 ± 49 0.014 0.84 ± 0.36 0.72 ± 0.30 0.028
Remote segments 148 ± 64 151 ± 61 0.6 0.67 ± 0.31 0.66 ± 0.26 0.76






mL/min/100gBefore CSWT After CSWT
Fig. 1 PET polartomograms of absolute perfusion under adenosine
of patient 1 (Table 3) before and after CSWT. In this case, the inferior
wall was treated. Perfusion of the target zone under adenosine was 91
before CSWT and 123 mL/min/100 g after therapy
Table 5 CCS class and perfusion data
CCS unchanged CCS improved
Perfusion shift\5 % 5 3
Perfusion shift C5 % 3 10
P = 0.16
Table 6 Echocardiographic measurements
Baseline Follow-up P
LVEDD (mm) 55 ± 7 53 ± 6 0.36
LVEDV (ml) 91 ± 34 96 ± 25 0.46
LVESV (ml) 47 ± 33 49 ± 24 0.29
LVEF (%) 54 ± 17 51 ± 14 0.74
LVEDD left-ventricular enddiastolic diameter, LVEDV left-ven-
tricular enddiastolic volume, LVESV left-ventricular endsystolic vol-
ume, LVEF left-ventricular ejection fraction
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with respect to the CCS classification, although no sig-
nificant changes in exercise tolerance were observed. To
what extent this improvement in CCS classification is a net
effect of reduced ischemic burden, and thus a relief of
angina symptoms, or is driven by changes in individual
perception needs further clarification. The present data
indicate that suggestive factors are likely to play a role as
38 % of those patients with no better perfusion of the target
segments experienced a CCS class downstaging.
Another issue of interest is the duration of the im-
provements, with the concept for future therapeutic courses
having to evaluate the frequency and duration of CSWT
and, finally, patient outcome.
The results of the present study are in line with former
imaging studies and demonstrate absolute effects of CSWT
on myocardial perfusion of the target zone [17]. The
clinical results, however, are more cautious than those of
other studies, but concordant to the global perfusion ana-
lysis which indicates that the underlying end-stage CAD
remains as expected and that a local noninvasive procedure
may not significantly improve an advanced stage of disease
[11, 13].
To summarize the results of the present study: CSWT
has the potential to improve myocardial perfusion of the
target therapy zone and CAD symptomatology without
affecting global myocardial perfusion and morphologic
ventricular parameters. As a noninvasive and well tolerated
therapeutic option, our data suggest the use of CSWT in
patients with end-stage CAD.
Study limitations
From a statistical point of view, the patient number is
sufficient to identify differences in perfusion with PET
imaging and mildly larger than in other studies with nu-
clear medicine imaging. Nevertheless, larger patient co-
horts with longer follow-ups are needed to further evaluate
the efficacy of CSWT. A placebo-controlled group is
missing. However, the intraindividual comparison of
treated vs nontreated zones tried to circumnavigate this
issue.
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